Our study was not powered to detect such differences, and the results may be due to other causes, such as confounding by indication (i.e., more people with diabetes who had gastrointestinal symptoms due to other causes may fail on metformin and/or GLP-1 receptor agonists and hence receive DPP-4 inhibitors). This evidence concerns the gene GLP1R and diabetes mellitus.